Research graph
References from CD200–CD200R as a myeloid immune checkpoint in solid tumors: mechanisms, context-dependent functions, and therapeutic opportunities. Local targets link to admitted publications; unresolved targets remain external evidence.
The future of immune checkpoint therapy
10.1126/science.aaa8172 · 2015 · External reference
Immune checkpoint blockade: a common denominator approach to cancer therapy
10.1016/j.ccell.2015.03.001 · 2015 · External reference
SIRPalpha-CD47 immune checkpoint blockade in anticancer therapy
10.1016/j.it.2017.12.005 · 2018 · External reference
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
10.1073/pnas.1121623109 · 2012 · External reference
Down-regulation of the macrophage lineage through interaction with OX2 (CD200)
10.1126/science.290.5497.1768 · 2000 · External reference
Regulation of myeloid cell function through the CD200 receptor
10.4049/jimmunol.176.1.191 · 2006 · External reference
Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function
10.1016/s1074-7613(00)00023-6 · 2000 · External reference
Myeloid cell-targeted therapies for solid tumours
10.1038/s41577-022-00737-w · 2023 · External reference
CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPalpha-CD47 to suppress tumor growth
10.1038/s41467-025-60456-3 · 2025 · External reference
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
10.1186/s40425-019-0710-1 · 2019 · External reference
CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy
10.4049/jimmunol.178.9.5595 · 2007 · External reference
CD200R signaling contributes to unfavorable tumor microenvironment through regulating production of chemokines by tumor-associated myeloid cells
10.1016/j.isci.2023.106904 · 2023 · External reference
A critical role for CD200R signaling in limiting the growth and metastasis of CD200+ melanoma
10.4049/jimmunol.1600052 · 2016 · External reference
CD200 blockade modulates tumor immune microenvironment but fails to show efficacy in inhibiting tumor growth in a murine model of melanoma
10.3389/fcell.2021.739816 · 2021 · External reference
CD200/CD200R: Bidirectional role in cancer progression and immunotherapy
10.3390/biomedicines11123326 · 2023 · External reference
The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy
10.18632/oncotarget.28354 · 2023 · External reference
First-in-human study of 23ME-00610, an antagonistic antibody for genetically validated CD200R1 immune checkpoint, in participants with advanced solid Malignancies
10.1158/2767-9764.crc-24-0568 · 2025 · External reference
Role of a distal enhancer in the transcriptional responsiveness of the human CD200 gene to interferon-gamma and tumor necrosis factor-alpha
10.1016/j.molimm.2009.03.015 · 2009 · External reference
CD200:CD200R interactions and their importance in immunoregulation
10.3390/ijms22041602 · 2021 · External reference
Characterization of CD200 ectodomain shedding
10.1371/journal.pone.0152073 · 2016 · External reference
CD200 and membrane protein interactions in the control of myeloid cells
10.1016/s1471-4906(02)02223-8 · 2002 · External reference
CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia
10.1038/leu.2011.1 · 2011 · External reference
Characterization of the CD200 receptor family in mice and humans and their interactions with CD200
10.4049/jimmunol.171.6.3034 · 2003 · External reference
Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells
10.4049/jimmunol.0901531 · 2009 · External reference
Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells
10.4049/jimmunol.162.2.774 · 1999 · External reference
Augmented induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R
10.1097/01.tp.0000152118.51622.f9 · 2005 · External reference
Role of CD200/CD200R signaling pathway in regulation of CD4+T cell subsets during thermal ablation of hepatocellular carcinoma
10.12659/msm.913094 · 2019 · External reference
CD200 is induced by ERK and is a potential therapeutic target in melanoma
10.1172/jci32163 · 2007 · External reference
A critical function for CD200 in lung immune homeostasis and the severity of influenza infection
10.1038/ni.1637 · 2008 · External reference
Over-expression of CD200 predicts poor prognosis in cutaneous squamous cell carcinoma
10.12659/msm.895245 · 2016 · External reference
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy
10.1186/s40425-014-0046-9 · 2014 · External reference
Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade
10.3389/fonc.2023.1088038 · 2023 · External reference
CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor
10.1038/onc.2011.477 · 2012 · External reference
Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells
10.1038/leu.2012.75 · 2012 · External reference
CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis
10.1172/jci150750 · 2022 · External reference
CD200R signaling in tumor tolerance and inflammation: A tricky balance
10.1016/j.coi.2012.01.002 · 2012 · External reference
Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions
10.1371/journal.pone.0031442 · 2012 · External reference
Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy
10.1002/eji.201040472 · 2010 · External reference
Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response
10.1038/onc.2014.317 · 2015 · External reference
Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6
10.1007/s10549-012-2258-3 · 2012 · External reference
CD200 is overexpressed in neuroblastoma and regulates tumor immune microenvironment
10.1007/s00262-020-02589-6 · 2020 · External reference
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
10.1016/s1470-2045(18)30578-3 · 2018 · External reference
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
10.1038/nm.3337 · 2013 · External reference
Regression of glioblastoma after chimeric antigen receptor T-cell therapy
10.1056/nejmoa1610497 · 2016 · External reference
The CD200-CD200R axis promotes squamous cell carcinoma metastasis via regulation of cathepsin K
10.1158/0008-5472.can-20-3251 · 2021 · External reference
Targeting tumor-associated macrophages in head and neck squamous cell carcinoma
10.1016/j.oraloncology.2020.104723 · 2020 · External reference
The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma
10.1158/0008-5472.can-09-4380 · 2010 · External reference
Local adenoviral delivery of soluble CD200R-Ig enhances antitumor immunity by inhibiting CD200-beta-catenin-driven M2 macrophage
10.1016/j.omto.2021.09.001 · 2021 · External reference
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
10.1056/nejmoa1602252 · 2016 · External reference
CD200R blockade enhances anti-tumor immunity by unleashing NK and CD8+ T cells in tumor
10.1038/s41401-025-01556-0 · 2025 · External reference
Combination CD200R/PD-1 blockade in a humanised mouse model
10.1093/immadv/ltad006 · 2023 · External reference
CD200 promotes immunosuppression in the pancreatic tumor microenvironment
10.1136/jitc-2019-000189 · 2020 · External reference
CD200 expression in neuroendocrine neoplasms
10.1093/ajcp/aqx071 · 2017 · External reference
Multiplex quantitative analysis of tumor-infiltrating lymphocytes, cancer-associated fibroblasts, and CD200 in pancreatic cancer
10.3390/cancers13215501 · 2021 · External reference
Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200
10.1007/s00262-007-0429-6 · 2008 · External reference
Analysis of intra-tumoral macrophages and T cells in non-small cell lung cancer (NSCLC) indicates a role for immune checkpoint and CD200-CD200R interactions
10.3390/cancers13081788 · 2021 · External reference
Quantitative assessment of CD200 and CD200R expression in lung cancer
10.3390/cancers13051024 · 2021 · External reference
Primary and acquired resistance against immune check inhibitors in non-small cell lung cancer
10.3390/cancers14143294 · 2022 · External reference
Renal cell carcinoma
10.1016/s0140-6736(24)00917-6 · 2024 · External reference
ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
10.1186/1471-2407-8-179 · 2008 · External reference
NK cell-based immunotherapy in renal cell carcinoma
10.3390/cancers12020316 · 2020 · External reference
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
10.1016/j.cell.2010.07.044 · 2010 · External reference
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
10.1073/pnas.1305569110 · 2013 · External reference
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
10.1038/s41586-019-1456-0 · 2019 · External reference
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
10.1038/s41590-017-0004-z · 2018 · External reference
Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
10.1093/abt/tbab002 · 2021 · External reference
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
10.1038/s41591-019-0374-x · 2019 · External reference
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy
10.1016/j.ccr.2014.05.016 · 2014 · External reference
Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity
10.1016/j.celrep.2015.04.031 · 2015 · External reference
An orally available non-nucleotide STING agonist with antitumor activity
10.1126/science.aba6098 · 2020 · External reference
Targeting macrophages: therapeutic approaches in cancer
10.1038/nrd.2018.169 · 2018 · External reference
CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival
10.1007/s00262-024-03678-6 · 2024 · External reference
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
10.1038/ncomms12150 · 2016 · External reference
Myeloid-derived suppressor cells as regulators of the immune system
10.1038/nri2506 · 2009 · External reference
Targeting the myeloid checkpoint receptor SIRPalpha potentiates innate and adaptive immune responses to promote anti-tumor activity
10.1186/s13045-020-00989-w · 2020 · External reference
Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy
10.1002/eji.201040472 · ExternalCitation · doi-reference
Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200
10.1007/s00262-007-0429-6 · ExternalCitation · doi-reference
CD200 is overexpressed in neuroblastoma and regulates tumor immune microenvironment
10.1007/s00262-020-02589-6 · ExternalCitation · doi-reference
CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival
10.1007/s00262-024-03678-6 · ExternalCitation · doi-reference
Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6
10.1007/s10549-012-2258-3 · ExternalCitation · doi-reference
Immune checkpoint blockade: a common denominator approach to cancer therapy
10.1016/j.ccell.2015.03.001 · ExternalCitation · doi-reference
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy
10.1016/j.ccr.2014.05.016 · ExternalCitation · doi-reference
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
10.1016/j.cell.2010.07.044 · ExternalCitation · doi-reference
Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity
10.1016/j.celrep.2015.04.031 · ExternalCitation · doi-reference
CD200R signaling in tumor tolerance and inflammation: A tricky balance
10.1016/j.coi.2012.01.002 · ExternalCitation · doi-reference
CD200R signaling contributes to unfavorable tumor microenvironment through regulating production of chemokines by tumor-associated myeloid cells
10.1016/j.isci.2023.106904 · ExternalCitation · doi-reference
SIRPalpha-CD47 immune checkpoint blockade in anticancer therapy
10.1016/j.it.2017.12.005 · ExternalCitation · doi-reference
Role of a distal enhancer in the transcriptional responsiveness of the human CD200 gene to interferon-gamma and tumor necrosis factor-alpha
10.1016/j.molimm.2009.03.015 · ExternalCitation · doi-reference
Local adenoviral delivery of soluble CD200R-Ig enhances antitumor immunity by inhibiting CD200-beta-catenin-driven M2 macrophage
10.1016/j.omto.2021.09.001 · ExternalCitation · doi-reference
Targeting tumor-associated macrophages in head and neck squamous cell carcinoma
10.1016/j.oraloncology.2020.104723 · ExternalCitation · doi-reference
Renal cell carcinoma
10.1016/s0140-6736(24)00917-6 · ExternalCitation · doi-reference
Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function
10.1016/s1074-7613(00)00023-6 · ExternalCitation · doi-reference
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
10.1016/s1470-2045(18)30578-3 · ExternalCitation · doi-reference
CD200 and membrane protein interactions in the control of myeloid cells
10.1016/s1471-4906(02)02223-8 · ExternalCitation · doi-reference
CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia
10.1038/leu.2011.1 · ExternalCitation · doi-reference
Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells
10.1038/leu.2012.75 · ExternalCitation · doi-reference
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
10.1038/ncomms12150 · ExternalCitation · doi-reference
A critical function for CD200 in lung immune homeostasis and the severity of influenza infection
10.1038/ni.1637 · ExternalCitation · doi-reference
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
10.1038/nm.3337 · ExternalCitation · doi-reference
Targeting macrophages: therapeutic approaches in cancer
10.1038/nrd.2018.169 · ExternalCitation · doi-reference
Myeloid-derived suppressor cells as regulators of the immune system
10.1038/nri2506 · ExternalCitation · doi-reference
CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor
10.1038/onc.2011.477 · ExternalCitation · doi-reference
Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response
10.1038/onc.2014.317 · ExternalCitation · doi-reference
CD200R blockade enhances anti-tumor immunity by unleashing NK and CD8+ T cells in tumor
10.1038/s41401-025-01556-0 · ExternalCitation · doi-reference
CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPalpha-CD47 to suppress tumor growth
10.1038/s41467-025-60456-3 · ExternalCitation · doi-reference
Myeloid cell-targeted therapies for solid tumours
10.1038/s41577-022-00737-w · ExternalCitation · doi-reference
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
10.1038/s41586-019-1456-0 · ExternalCitation · doi-reference
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
10.1038/s41590-017-0004-z · ExternalCitation · doi-reference
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
10.1038/s41591-019-0374-x · ExternalCitation · doi-reference
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
10.1056/nejmoa1602252 · ExternalCitation · doi-reference
Regression of glioblastoma after chimeric antigen receptor T-cell therapy
10.1056/nejmoa1610497 · ExternalCitation · doi-reference
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
10.1073/pnas.1121623109 · ExternalCitation · doi-reference
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
10.1073/pnas.1305569110 · ExternalCitation · doi-reference
Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
10.1093/abt/tbab002 · ExternalCitation · doi-reference
CD200 expression in neuroendocrine neoplasms
10.1093/ajcp/aqx071 · ExternalCitation · doi-reference
Combination CD200R/PD-1 blockade in a humanised mouse model
10.1093/immadv/ltad006 · ExternalCitation · doi-reference
Augmented induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R
10.1097/01.tp.0000152118.51622.f9 · ExternalCitation · doi-reference
Down-regulation of the macrophage lineage through interaction with OX2 (CD200)
10.1126/science.290.5497.1768 · ExternalCitation · doi-reference
The future of immune checkpoint therapy
10.1126/science.aaa8172 · ExternalCitation · doi-reference
An orally available non-nucleotide STING agonist with antitumor activity
10.1126/science.aba6098 · ExternalCitation · doi-reference
CD200 promotes immunosuppression in the pancreatic tumor microenvironment
10.1136/jitc-2019-000189 · ExternalCitation · doi-reference
The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma
10.1158/0008-5472.can-09-4380 · ExternalCitation · doi-reference
The CD200-CD200R axis promotes squamous cell carcinoma metastasis via regulation of cathepsin K
10.1158/0008-5472.can-20-3251 · ExternalCitation · doi-reference
First-in-human study of 23ME-00610, an antagonistic antibody for genetically validated CD200R1 immune checkpoint, in participants with advanced solid Malignancies
10.1158/2767-9764.crc-24-0568 · ExternalCitation · doi-reference
CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis
10.1172/jci150750 · ExternalCitation · doi-reference
CD200 is induced by ERK and is a potential therapeutic target in melanoma
10.1172/jci32163 · ExternalCitation · doi-reference
ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
10.1186/1471-2407-8-179 · ExternalCitation · doi-reference
Targeting the myeloid checkpoint receptor SIRPalpha potentiates innate and adaptive immune responses to promote anti-tumor activity
10.1186/s13045-020-00989-w · ExternalCitation · doi-reference
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy
10.1186/s40425-014-0046-9 · ExternalCitation · doi-reference
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
10.1186/s40425-019-0710-1 · ExternalCitation · doi-reference
Over-expression of CD200 predicts poor prognosis in cutaneous squamous cell carcinoma
10.12659/msm.895245 · ExternalCitation · doi-reference
Role of CD200/CD200R signaling pathway in regulation of CD4+T cell subsets during thermal ablation of hepatocellular carcinoma
10.12659/msm.913094 · ExternalCitation · doi-reference
Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions
10.1371/journal.pone.0031442 · ExternalCitation · doi-reference
Characterization of CD200 ectodomain shedding
10.1371/journal.pone.0152073 · ExternalCitation · doi-reference
The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy
10.18632/oncotarget.28354 · ExternalCitation · doi-reference
CD200 blockade modulates tumor immune microenvironment but fails to show efficacy in inhibiting tumor growth in a murine model of melanoma
10.3389/fcell.2021.739816 · ExternalCitation · doi-reference
Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade
10.3389/fonc.2023.1088038 · ExternalCitation · doi-reference
CD200/CD200R: Bidirectional role in cancer progression and immunotherapy
10.3390/biomedicines11123326 · ExternalCitation · doi-reference
NK cell-based immunotherapy in renal cell carcinoma
10.3390/cancers12020316 · ExternalCitation · doi-reference
Quantitative assessment of CD200 and CD200R expression in lung cancer
10.3390/cancers13051024 · ExternalCitation · doi-reference
Analysis of intra-tumoral macrophages and T cells in non-small cell lung cancer (NSCLC) indicates a role for immune checkpoint and CD200-CD200R interactions
10.3390/cancers13081788 · ExternalCitation · doi-reference
Multiplex quantitative analysis of tumor-infiltrating lymphocytes, cancer-associated fibroblasts, and CD200 in pancreatic cancer
10.3390/cancers13215501 · ExternalCitation · doi-reference
Primary and acquired resistance against immune check inhibitors in non-small cell lung cancer
10.3390/cancers14143294 · ExternalCitation · doi-reference
CD200:CD200R interactions and their importance in immunoregulation
10.3390/ijms22041602 · ExternalCitation · doi-reference
Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells
10.4049/jimmunol.0901531 · ExternalCitation · doi-reference
A critical role for CD200R signaling in limiting the growth and metastasis of CD200+ melanoma
10.4049/jimmunol.1600052 · ExternalCitation · doi-reference
Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells
10.4049/jimmunol.162.2.774 · ExternalCitation · doi-reference
Characterization of the CD200 receptor family in mice and humans and their interactions with CD200
10.4049/jimmunol.171.6.3034 · ExternalCitation · doi-reference
Regulation of myeloid cell function through the CD200 receptor
10.4049/jimmunol.176.1.191 · ExternalCitation · doi-reference
CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy
10.4049/jimmunol.178.9.5595 · ExternalCitation · doi-reference
